Clinilabs announced that they have been selected to conduct a Phase I/II clinical research study of an investigational vaccine for HIV.
According to Dr. Howard Greenberg, Senior Medical Director of Clinilabs, "Conducting early phase clinical trials with a novel therapeutic in a new patient population is a major advance in Clinilabs’ progression as a CRU.”
Greenberg also notes that conducting vaccine studies and expanding enrollment of specialty patient populations are two key strategic directions Clinilabs is pursuing to capitalize on its position as a global CRO that operates a CRU in New York City, a hub of academic medical centers and home to a diverse population of more than 19 million potential research subjects.
Enrollment for this study is expected to begin later this month.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.